KORU Medical expects FY2021 revenue $23.0M-$23.2M; Q4 to show sequential growth

KORU Medical Systems, Inc.

Q4 2021 expected to be the fourth consecutive quarter of positive sequential revenue growth.
Full year 2021 revenue guidance of $23.0 million to $23.2 million.
Domestic SCIg market expected to recover to mid-to-high single digits in 2022.
Company expects its domestic SCIg revenue growth to be slightly ahead of the market recovery.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.